Intelligent Remote Intervention for High-risk Breast Cancer Populations

Launched by QIANFOSHAN HOSPITAL · Dec 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether a modern remote health intervention can be more effective than traditional in-person care for women at high risk of breast cancer. Specifically, it will look at women who have breast nodules classified as BI-RADS 3 or higher, which means they need closer monitoring. The trial will compare two groups: one that receives remote care, including video calls with doctors, wearable devices to monitor health, and educational apps, and another that follows the standard care guidelines, which mainly involve regular ultrasound checks.

To join the trial, women must be at least 18 years old and have breast nodules that fit the criteria. They should be able to use remote health tools, as those in the remote care group will rely on technology for consultations and monitoring. Participants can expect to be part of a study lasting two years, where they will receive either the new remote intervention or standard care. The trial aims to see if the remote approach can help slow down the growth of breast nodules, improve patients' knowledge about their condition, and ultimately reduce health risks.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female; Age\>=18; Having breast BI-RADS 3 nodules or higher; Informed consent signed.
• Exclusion Criteria:
• • Having any other known breast diseases; Having any major malignant diseases; Having no access to the remote devices or don't know how to use them.